Skip to main content

March 2016

 

 

academics

 

Clinical research courses

Multiple vacancies for Scientific positions in Indian Institute of Toxicology Research

The CSIR - Indian Institute of Toxicology Research (CSIR - IITR), Lucknow, a premier institute under the Council of Scientific and Industrial Research (CSIR) , is involved in multidisciplinary R&D programmes of both basic and applied nature across scientific disciplines for economic, environmental and societal benefits for the people of India. CSIR - IITR is engaged in the areas of Environmental Toxicology; Food, Drug and Chemical Toxicology; Systems Toxicology & Health Risk Assessment; Regulatory Toxicology; Nanotherapeutics & Nanomaterial Toxicology. CSIR-IITR has two campuses; the main campus is located at the centre of Lucknow City and the other campus at a distance of approx. 20 km from the main campus.

Applications for following Scientific positions are invited from enthusiastic, young Indian researchers having excellent academic record and proven scientific achievements along with requisite experience and a high degree of motivation and desire to take up research as a career in the above mentioned areas.

Job for Scientist, Senior Scientist in THSTI - 5 posts | Emolument up to Rs. 72000 / month

Translational Health Science and Technology Institute (THSTI), India and the International AIDS Vaccine Initiative (IAVI), USA have set up a collaborative program entitled“ HIV Vaccine Translational Research” (HVTR) to accelerate and advance HIV vaccine research and development. The program is an integral part of the THSTI cluster of research centers and linked to global network of R& D facilities, including IAVIs Neutralizing Antibody Consortium (NAC) and IAVI Design and Development lab, situated in Brooklyn, New York. The THSTI - IAVI HIV Vaccine Design Lab examines novel AIDS vaccine platforms and immunogens, standardizes preclinical testing of AIDS vaccine candidates, and develops candidates for evaluation in clinical trials. It is an innovative discovery program directed at designing, testing and implementing high - throughput (HT) strategies for HIV - 1 envelope - based immunogen screening and prioritization to help discover and advance novel HIV vaccine candidates. The program is targeted to expand the number of vaccine candidates for testing, and enhance the speed with which they can be assayed. The unique industrial - type high - throughput vaccine design, screening and selection processes proposed will be largely facilitated by interdisciplinary interaction and thus driven by principles of international collaboration, high - quality science and vaccine - oriented applied research.

To strengthen its research mission,  “HIV Vaccine Translational Research” (HVTR) is  seeking  to  fill  the  positions  of  Scientist  and  Senior  Scientist.  The  details  of  these positions are provided below.

Opportunity to work as Executive (IP Licensing) at IIT

IIT Bombay, set up by an Act of Parliament, was established in 1958, at Powai, a northern suburb of Mumbai. Today the Institute is recognised as one of the centres of academic excellence in the country. Over the years, there has been dynamic progress at IIT Bombay in all academic and research activities, and a parallel improvement in facilities and infrastructure, to keep it on par with the best institutions in the world. Institutes in positions of excellence grow with time. The ideas and ideals on which such institutes are built evolve and change with national aspirations, national perspectives, and trends world – wide. IIT Bombay, too, is one such institution.

Industrial Research and Consultancy Centre, IIT Bombay is looking for a talented and motivated Executives to help in enhancing intellectual property rights (IPR) management activities and related technical activities in research administration. In this regard, we are seeking committed manpower to help in IP protection / licensing activities and other research administration as per needs. Details of the post are given below:

Post: Executive (IP Licensing) (01 Post)

Opportunity to work as Scientist in World Health Organization

WHO is the directing and coordinating authority for health within the United Nations system. It is responsible for providing leadership on global health matters, shaping the health research agenda, setting norms and standards, articulating evidence-based policy options, providing technical support to countries and monitoring and assessing health trends.

Post: Scientist

Eagle Pharmaceuticals, Inc. announced that it has entered into an agreement with the National Institutes of Health (“NIH”)/National Institute on Drug Abuse (“NIDA”) to explore the use of Ryanodex® in the treatment of hyperthermia related to MDMA (“Ecstasy”) and Methamphetamine intoxication, which is a life-threatening condition mostly affecting adolescents and young adults.

TSO3 Inc. has received FDA 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a universal design of its STERIZONE® VP4 Sterilizer. The STERIZONE® VP4 Sterilizer was originally cleared for commercialization in the U.S. in December 2014. The new clearance enables the company to streamline assembly and shipping around a single sterilizer platform that meets global regulations for electromechanical design.

KemPharm, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted a fee waiver and has refunded the full user fee amount of $2,374,200 for its New Drug Application (NDA) filing for KP201/APAP, the Company’s investigational immediate release combination of its hydrocodone prodrug, KP201 (benzhydrocodone hydrochloride), and acetaminophen (APAP), which is currently under priority review by the FDA.  The FDA has set a target action date under the Prescription Drug User Fee Act of June 9, 2016.

MediciNova, Inc., and the JASDAQ Market of the Tokyo Stock Exchange announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia.